IONIQ Sciences Designated ‘Most Innovative Cancer Detection and Diagnostics Technology Firm’ by CV Magazine
December 14, 2020
12/10/2020 – IONIQ Sciences has been designated as 2020’s ‘Most Innovative Cancer Detection and Diagnostics Technology Firm’ by CV Magazine. Our goal to modernize cancer testing has taken us to exciting heights this year. We resolutely believe in our potential to introduce a ‘breakthrough’ Multi-Cancer Screen that will non-invasively detect the presence of malignancy in its earliest stages utilizing our Electrical Impedance Analytics (EIA) technology and proprietary algorithm. We imagine a future where cancer screening is point-of-care, accurate, and free of radiation. On behalf of the estimated 1.8 million people in the USA diagnosed with cancer in 2020, we’re fighting for this future every day.
Courtesy of IONIQSciences.com
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
